Results 251 to 260 of about 1,097,210 (332)

Doxorubicin‐Loaded Metal–Organic Framework for Ferroptosis‐Enhanced Chemotherapy Through Sustained Zn Release and Glutathione Peroxidase Downregulation

open access: yesAdvanced Healthcare Materials, EarlyView.
A robust zinc‐based metal–organic framework (ZnMOF) enables dual functions of doxorubicin delivery and sustained Zn2+ release to trigger ferroptosis‐enhnaced chemotherapy. DOX@ZnMOF effectively depletes intracellular glutathione, suppresses GPX4, and elevates reactive oxygen species, leading to efficient oxidative DNA damage and apoptosis.
Xin Ma   +5 more
wiley   +1 more source

CD318 expression defines a novel subset of human CD8<sup>+</sup> regulatory T cells. [PDF]

open access: yesSci Adv
Do JS   +8 more
europepmc   +1 more source

A 3D Bioprinted Spheroid‐Laden dECM‐Enriched Osteosarcoma Model for Enhanced Drug Testing and Therapeutic Discovery

open access: yesAdvanced Healthcare Materials, EarlyView.
A 3D biomimetic OS model was developed by bioprinting an OS‐cell‐derived dECM‐enriched bioink with OS spheroids incorporated. The model showed upregulation of known OS prognostic markers and increased resistance to doxorubicin, compared to 2D cultures and scaffold‐free spheroids, making this a more clinically relevant platform for drug discovery ...
Margarida F. Domingues   +6 more
wiley   +1 more source

Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia. [PDF]

open access: yesCancer Res Commun
Gravenmier C   +7 more
europepmc   +1 more source

Photosensitizing Lipid Nanoparticles for Ferroptosis‐Enhanced Photodynamic Cancer Therapy via GPX4 Silencing

open access: yesAdvanced Healthcare Materials, EarlyView.
Photosensitizing lipid nanoparticles (PLNPs) are engineered by incorporating cholesterol–PEG–pheophorbide a into MC3‐based LNPs and encapsulating GPX4‐targeting siRNA. Upon light activation, PLNPs generate reactive oxygen species (ROS) while silencing GPX4 to induce ferroptosis.
Ga‐Hyun Bae   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy